In yesterday’s Wall Street session, Climb Bio Inc (NASDAQ:CLYM) shares traded at $1.98, up 3.13% from the previous session.
CLYM stock price is now -42.26% away from the 50-day moving average and -65.00% away from the 200-day moving average. The market capitalization of the company currently stands at $139.83M.
With the price target of $10, Leerink Partners recently initiated with Outperform rating for Climb Bio Inc (NASDAQ: CLYM).
In other news, Pimblett Emily, CHIEF ACCOUNTING OFFICER sold 1,235 shares of the company’s stock on Dec 19 ’24. The stock was sold for $2,495 at an average price of $2.02. Upon completion of the transaction, the CHIEF ACCOUNTING OFFICER now directly owns 11,329 shares in the company, valued at $22431.42. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 20 ’24, CHIEF ACCOUNTING OFFICER Pimblett Emily sold 1,191 shares of the business’s stock. A total of $9,741 was realized by selling the stock at an average price of $8.18. This leaves the insider owning 7,564 shares of the company worth $14976.72. A total of 23.36% of the company’s stock is owned by insiders.
During the past 12 months, Climb Bio Inc has had a low of $1.86 and a high of $11.55. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 57.73, and a quick ratio of 57.73. The fifty day moving average price for CLYM is $3.4965 and a two-hundred day moving average price translates $5.660425 for the stock.
The latest earnings results from Climb Bio Inc (NASDAQ: CLYM) was released for 2024-09-30.
